Regeneron’s COVID-19 Antibody Cocktail Shows Early Promise, But Does It Merit An EUA?

Could Help Patients Who Lack Own Antibody Response

 
• By Andrew McConaghie
  
Covid test
Serology tests found around 40% of trial patients had generated no antibodies against the disease - making them higher risk, and more likely to benefit from REGN-COV2.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Archive

More from Scrip